Literature DB >> 28637259

Caddyshack therapeutics: overcoming glioblastoma adaptation.

David H Gutmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28637259      PMCID： PMC5737573          DOI： 10.1093/neuonc/nox096

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Authors:  Xiao-Hong Ma; Sheng-Fu Piao; Souvik Dey; Quentin McAfee; Giorgos Karakousis; Jessie Villanueva; Lori S Hart; Samuel Levi; Janice Hu; Gao Zhang; Rossitza Lazova; Vincent Klump; John M Pawelek; Xiaowei Xu; Wei Xu; Lynn M Schuchter; Michael A Davies; Meenhard Herlyn; Jeffrey Winkler; Constantinos Koumenis; Ravi K Amaravadi
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

2.  An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis.

Authors:  Smita Matkar; Paras Sharma; Shubin Gao; Buddha Gurung; Bryson W Katona; Jennifer Liao; Abdul Bari Muhammad; Xiang-Cheng Kong; Lei Wang; Guanghui Jin; Chi V Dang; Xianxin Hua
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

3.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

4.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

5.  An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Authors:  Alicia S Chung; Xiumin Wu; Guanglei Zhuang; Hai Ngu; Ian Kasman; Jianhuan Zhang; Jean-Michel Vernes; Zhaoshi Jiang; Y Gloria Meng; Franklin V Peale; Wenjun Ouyang; Napoleone Ferrara
Journal:  Nat Med       Date:  2013-08-04       Impact factor: 53.440

Review 6.  Contextual signaling in cancer.

Authors:  Laura J Smithson; Corina Anastasaki; Ran Chen; Joseph A Toonen; Sidney B Williams; David H Gutmann
Journal:  Semin Cell Dev Biol       Date:  2016-06-03       Impact factor: 7.727

7.  Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.

Authors:  J Bertacchini; M Guida; B Accordi; L Mediani; A M Martelli; P Barozzi; E Petricoin; L Liotta; G Milani; M Giordan; M Luppi; F Forghieri; A De Pol; L Cocco; G Basso; S Marmiroli
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528

8.  Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Authors:  Gary L Johnson; Timothy J Stuhlmiller; Steven P Angus; Jon S Zawistowski; Lee M Graves
Journal:  Clin Cancer Res       Date:  2014-03-24       Impact factor: 12.531

9.  Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Authors:  Alex Kentsis; Casie Reed; Kim L Rice; Takaomi Sanda; Scott J Rodig; Eleni Tholouli; Amanda Christie; Peter J M Valk; Ruud Delwel; Vu Ngo; Jeffery L Kutok; Suzanne E Dahlberg; Lisa A Moreau; Richard J Byers; James G Christensen; George Vande Woude; Jonathan D Licht; Andrew L Kung; Louis M Staudt; A Thomas Look
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

10.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Authors:  Robert S McNeill; Demitra A Canoutas; Timothy J Stuhlmiller; Harshil D Dhruv; David M Irvin; Ryan E Bash; Steven P Angus; Laura E Herring; Jeremy M Simon; Kasey R Skinner; Juanita C Limas; Xin Chen; Ralf S Schmid; Marni B Siegel; Amanda E D Van Swearingen; Michael J Hadler; Erik P Sulman; Jann N Sarkaria; Carey K Anders; Lee M Graves; Michael E Berens; Gary L Johnson; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.